VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. | VC Versant Ventures is ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Solventum estimates that Acera will likely post about $90 million in sales for 2025. The deal is expected to be "slightly dilutive" to adjusted earnings per share in 2026 and accretive to adjusted ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market ...